Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitophagy is the selective degradation of mitochondria by autophagy, a process essential for maintaining cellular health and homeostasis. It specifically targets damaged or superfluous mitochondria, delivering them to lysosomes for breakdown and recycling. This process is evolutionarily conserved from yeast to humans and plays a critical role in mitochondrial quality control, energy metabolism adaptation, development (such as red blood cell maturation), and prevention of cellular degeneration. It involves recognition of damaged mitochondria, autophagosome formation, and fusion with lysosomes. Key pathways include PINK1-Parkin, BNIP3/NIX, and FUNDC1. Dysregulation of mitophagy contributes to various diseases, including neurodegeneration, cardiovascular disease, and metabolic disorders.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitophagy (None).